Table 5 Adverse events (N = 36).

From: Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study

  G1 G2 G3 G4 Grade ≥ 1 % Grade ≥ 3 %
Hypertension 10 3 1 0 14 38.9% 1 2.8%
Proteinuria 10 2 1 0 13 36.1% 1 2.8%
Hand-foot syndrome 1 3 2 1 7 19.4% 3 8.3%
Leukopenia 8 3 1 0 12 33.3% 1 2.8%
Neutropenia 4 4 0 0 8 22.2% 0 0.0%
Anemia 3 1 2 0 6 16.7% 2 5.6%
Thrombocytopenia 4 2 1 0 7 19.4% 1 2.8%
Elevated transaminase 3 4 1 0 8 22.2% 1 2.8%
Hyperbilirubinemia 5 3 0 0 8 22.2% 0 0.0%
Bleeding 2 0 0 0 2 5.6% 0 0.0%
Nausea and Vomiting 6 7 0 0 13 36.1% 0 0.0%
Diarrhea 5 2 2 0 9 25.0% 2 5.6%
Fatigue 5 2 0 0 7 19.4% 0 0.0%